---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-148651"
form_type: "8-K"
ticker: "ACLX"
cik: "0001786205"
company_name: "Arcellx, Inc."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T19:01:54.634432+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arcellx Q1 net loss $32.4M; CART-ddBCMA 100% ORR; doses first ACLX-001 patient

## Summary
- Q1 net loss $32.4M (vs $11.3M Q1 2021); R&D expense $24.4M (+$15.9M).
- Cash and marketable securities $210.9M as of Mar 31; funds operations into H2 2023.
- First patient dosed in Phase 1 of ACLX-001 (ARC-SparX) for relapsed/refractory multiple myeloma.
- CART-ddBCMA Phase 1 data published in Blood Advances: 100% ORR, 75% CR/sCR.
- CART-ddBCMA oral abstract at ASCO June 5; data on ~25 patients to be presented.

## SEC filing metadata
- accession: 0001193125-22-148651
- form_type: 8-K
- ticker: ACLX
- cik: 0001786205
- company_name: Arcellx, Inc.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1786205/000119312522148651/0001193125-22-148651-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1786205/000119312522148651/d338467d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-148651
- JSON: https://secwatch.observer/filing/0001193125-22-148651.json
- Plain text: https://secwatch.observer/filing/0001193125-22-148651.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.